Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,965,632 papers from all fields of science
Search
Sign In
Create Free Account
IDO Inhibitor NLG919
Known as:
GDC-0919
, NLG-919
, NLG919
An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers
Shoujun Chen
,
Fengtao Liu
,
+31 authors
Daxing Gao
Clinical research
2018
Corpus ID: 81756040
Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing…
Expand
2018
2018
IDO/TDO Inhibition in Cancer
G. Prendergast
,
William P. Malachowski
,
A. Mondal
,
P. Scherle
,
A. Muller
2018
Corpus ID: 80048341
Elevated tryptophan catabolism in many human tumors occurs due to activation of indoleamine 2,3-dioxygenase-1 (IDO1) or…
Expand
2018
2018
Abstract 2763: Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma
Pravin Kesawani
,
Antony H. Prabhu
,
+6 authors
Prakash Chinnaiyan
Immunology
2018
Corpus ID: 268659664
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options. Immune checkpoint inhibitors designed to revert…
Expand
2017
2017
GDC-0919 Modulates Tryptophan Metabolism in Glioblastoma and Enhances Radiation Response
P. Kesarwani
,
Praveen Kumar
,
+4 authors
P. Chinnaiyan
2017
Corpus ID: 79492420
2016
2016
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
D. Lazarus
,
Christian G Peters
,
Adam Stockmann
,
S. Eliasof
,
L. Jayaraman
2016
Corpus ID: 78582759
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically…
Expand
2015
2015
346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors
Asha Nayak
,
Zhonglin Hao
,
+16 authors
S. Khleif
2015
Corpus ID: 57454105
2014
2014
A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
Asha Nayak
,
Zhonglin Hao
,
+13 authors
S. Khleif
Journal of Immunotherapy for Cancer
2014
Corpus ID: 44346057
Meeting abstracts Clinical Trial Registration Number: [NCT02048709][1] The enzyme Indoleamine 2,3-dioxygenase (IDO1) catalyzes…
Expand
2014
2014
Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
Grégory Driessens
,
S. Crosignani
,
M. Detheux
,
B. J. Van den Eynde
,
S. Cauwenberghs
Journal of Immunotherapy for Cancer
2014
Corpus ID: 32890706
iTeos leverages the science of the LICR to target the metabolism of the tumor microenvironment and develops small-molecule…
Expand
2010
2010
Plangebied Sophiapolder, gemeente Hendrik-Ido-Ambacht; archeologisch vooronderzoek: een inventariserend veldonderzoek (verkennende en karterende fase) : RAAP-RAPPORT 2134
Raap Archeologisch Adviesbureau
,
C. Coppens
,
J. Eijk
,
J. Sprangers
,
K. Wink
,
R. Boer
2010
Corpus ID: 194904652
In opdracht van Rijkswaterstaat, dienst Zuid-Holland, heeft RAAP Archeologisch Adviesbureau in januari en mei 2010 een…
Expand
2004
2004
Enzymatische Acetylierung von D-Tryptophan
M. Zenk
,
J. Schmitt
Die Naturwissenschaften
2004
Corpus ID: 28413238
50%igen U b e r s c h u g Th iony lch lo r id 4 mill bei 50 ~ uild d a n n 2 S td bei R a u m t e m p e r a t u r . Das h i e r d…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE